Cubist Systematic Strategies LLC Sells 2,650 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC

Cubist Systematic Strategies LLC reduced its holdings in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) by 5.3% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 47,249 shares of the company’s stock after selling 2,650 shares during the quarter. Cubist Systematic Strategies LLC owned 0.07% of Bicycle Therapeutics worth $401,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BCYC. Barclays PLC boosted its holdings in shares of Bicycle Therapeutics by 878.3% in the 4th quarter. Barclays PLC now owns 2,612 shares of the company’s stock worth $37,000 after purchasing an additional 2,345 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Bicycle Therapeutics by 879.5% during the 1st quarter. GAMMA Investing LLC now owns 8,982 shares of the company’s stock worth $76,000 after acquiring an additional 8,065 shares during the period. Exchange Traded Concepts LLC grew its holdings in shares of Bicycle Therapeutics by 90.3% during the 1st quarter. Exchange Traded Concepts LLC now owns 12,764 shares of the company’s stock worth $108,000 after acquiring an additional 6,057 shares during the period. Cerity Partners LLC purchased a new position in shares of Bicycle Therapeutics during the 1st quarter worth approximately $113,000. Finally, Portland Investment Counsel Inc. purchased a new stake in shares of Bicycle Therapeutics in the 1st quarter worth approximately $127,000. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Oppenheimer reiterated an “outperform” rating and set a $44.00 target price (down from $48.00) on shares of Bicycle Therapeutics in a research note on Monday, August 11th. Morgan Stanley decreased their target price on Bicycle Therapeutics from $17.00 to $13.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 12th. JMP Securities cut their price objective on Bicycle Therapeutics from $22.00 to $10.00 and set a “market outperform” rating for the company in a research report on Tuesday, August 12th. Finally, Royal Bank Of Canada set a $27.00 price objective on Bicycle Therapeutics and gave the company an “outperform” rating in a research report on Monday, August 11th. Six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Bicycle Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $22.22.

Bicycle Therapeutics Price Performance

Shares of BCYC opened at $7.00 on Thursday. The firm has a market capitalization of $484.75 million, a PE ratio of -1.99 and a beta of 1.41. Bicycle Therapeutics PLC Sponsored ADR has a 1-year low of $6.10 and a 1-year high of $28.67. The company’s fifty day moving average price is $7.65 and its 200-day moving average price is $8.17.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Friday, August 8th. The company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19). Bicycle Therapeutics had a negative net margin of 1,257.00% and a negative return on equity of 32.43%. The company had revenue of $2.90 million for the quarter, compared to analysts’ expectations of $9.43 million. As a group, research analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 EPS for the current fiscal year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.